Cargando…

Prognostic impact of p53 and/or NY‐ESO‐1 autoantibody induction in patients with gastroenterological cancers

BACKGROUND AND AIM: We evaluated the clinicopathological and prognostic significance of serum p53 (s‐p53‐Abs) and serum NY‐ESO‐1 autoantibodies (s‐NY‐ESO‐1‐Abs) in esophageal squamous cell carcinoma (ESCC), gastric cancer and hepatocellular carcinoma (HCC). PATIENTS AND METHODS: A total of 377 patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoshino, Isamu, Nabeya, Yoshihiro, Takiguchi, Nobuhiro, Gunji, Hisashi, Ishige, Fumitaka, Iwatate, Yosuke, Shiratori, Fumiaki, Yajima, Satoshi, Okada, Rei, Shimada, Hideaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7240143/ https://www.ncbi.nlm.nih.gov/pubmed/32490341 http://dx.doi.org/10.1002/ags3.12325

Ejemplares similares

Inducing multiple antibodies to treat squamous cell esophageal carcinoma
por: Hoshino, Isamu, et al.
Publicado: (2020)

A case of Barrett’s esophageal cancer with gastric mucosa-associated lymphoma
por: Shiratori, Fumiaki, et al.
Publicado: (2020)

Usefulness of serum miR-1246/miR-106b ratio in patients with esophageal squamous cell carcinoma
por: Hoshino, Isamu, et al.
Publicado: (2020)

Surgical treatment strategy for esophagogastric junction cancers based on the tumor diameter
por: Hoshino, Isamu, et al.
Publicado: (2019)

Possible predictive significance of serum RalA autoantibodies on relapse-free survival in patients with colorectal cancer
por: Ushigome, Mitsunori, et al.
Publicado: (2021)

Cell-free microRNA-1246 in different body fluids as a diagnostic biomarker for esophageal squamous cell carcinoma
por: Hoshino, Isamu, et al.
Publicado: (2021)

Panel of autoantibodies against multiple tumor‐associated antigens for detecting gastric cancer
por: Hoshino, Isamu, et al.
Publicado: (2017)

Prevalence of serum galectin-1 autoantibodies in seven types of cancer: A potential biomarker
por: Nanami, Tatsuki, et al.
Publicado: (2021)

Adenocarcinoma originating from long-segment Barrett's esophagus over 15 cm: a series of 3 cases
por: Kuwayama, Naoki, et al.
Publicado: (2020)

Laparoscopic ileo-transverse bypass may contribute to achieving curative resection for locally advanced right colon cancer: a case report
por: Tabe, Shunsuke, et al.
Publicado: (2021)

Tumor-Infiltrating T Cells Correlate with NY-ESO-1-Specific Autoantibodies in Ovarian Cancer
por: Milne, Katy, et al.
Publicado: (2008)

Anti-NY-ESO-1 autoantibody may be a tumor marker for intrahepatic cholangiocarcinoma
por: Zhang, Zhen, et al.
Publicado: (2017)

Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients
por: Kageyama, Shinichi, et al.
Publicado: (2013)

Residual esophageal necrosis after radical esophagectomy for esophagogastric cancer: A case report
por: Tabe, Shunsuke, et al.
Publicado: (2020)

A right pulmonary vein abnormality treated with 3D CT assistance in thoracoscopic surgery for esophageal cancer: a case report
por: Kuwayama, Naoki, et al.
Publicado: (2022)

Efficacy of thoracotomy and thoracoscopic-assisted esophageal surgery in conversion and salvage surgeries: a retrospective study
por: Hoshino, Isamu, et al.
Publicado: (2022)

Radiogenomics predicts the expression of microRNA-1246 in the serum of esophageal cancer patients
por: Hoshino, Isamu, et al.
Publicado: (2020)

MIR1246 in body fluids as a biomarker for pancreatic cancer
por: Ishige, Fumitaka, et al.
Publicado: (2020)

NY-ESO-1 antibody as a novel tumour marker of gastric cancer
por: Fujiwara, S, et al.
Publicado: (2013)

Combination of autoantibodies against NY-ESO-1 and viral capsid antigen immunoglobulin A for improved detection of nasopharyngeal carcinoma
por: PENG, YU-HUI, et al.
Publicado: (2014)

NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
por: Thomas, Remy, et al.
Publicado: (2018)

CA19-9-producing esophageal adenocarcinoma originating from the esophageal cardia of the mid-thoracic esophagus: a case report
por: Kuwayama, Naoki, et al.
Publicado: (2021)

Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells
por: Gong, Wenjie, et al.
Publicado: (2021)

Prevalence of plasma autoantibody against cancer testis antigen NY-ESO-1 in HTLV-1 infected individuals with different clinical status
por: Shiohama, Yasuo, et al.
Publicado: (2017)

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma
por: Giesen, Eva, et al.
Publicado: (2014)

NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target
por: Lai, Jin-Ping, et al.
Publicado: (2012)

NY-ESO-1 expression in DCIS: A new predictor of good prognosis
por: Coombes, R. Charles, et al.
Publicado: (2017)

Involvement of NY-ESO-1 and MAGE-A4 in the pathogenesis of desmoid tumors
por: Hashimoto, Kazuhiko, et al.
Publicado: (2023)

Pushing forward in sarcoma with a new TCR targeting NY-ESO-1
por: Al-Marayaty, Rusul, et al.
Publicado: (2023)

Radiogenomics for predicting p53 status, PD-L1 expression, and prognosis with machine learning in pancreatic cancer
por: Iwatate, Yosuke, et al.
Publicado: (2020)

Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4(+)T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma
por: Jäger, Elke, et al.
Publicado: (2000)

Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141(+) dendritic cells to activate naïve and memory NY-ESO-1-specific CD8(+) T cells
por: Masterman, Kelly-Anne, et al.
Publicado: (2020)

First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors
por: Ishihara, Mikiya, et al.
Publicado: (2020)

NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability
por: Sommermeyer, Daniel, et al.
Publicado: (2013)

Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma
por: Gyurdieva, Alexandra, et al.
Publicado: (2022)

Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment
por: Zhou, Hong, et al.
Publicado: (2023)

Prediction of the differences in tumor mutation burden between primary and metastatic lesions by radiogenomics
por: Hoshino, Isamu, et al.
Publicado: (2021)

Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma
por: Dyrskjøt, L, et al.
Publicado: (2012)

Deep phenotypic characterization of NY-ESO TCR engineered T cells and tumor in patients with advanced myeloma
por: Davila, Eduardo, et al.
Publicado: (2015)

Increased NY-ESO-1 Expression and Reduced Infiltrating CD3+ T Cells in Cutaneous Melanoma
por: Giavina-Bianchi, Mara, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_tgbk0hu9ma2s0aiv2b196s94po